v3.26.1
Consolidated Statements of Cash Flows - DIAMIR BIOSCIENCES CORP. - USD ($)
 9 Months Ended 12 Months Ended
Feb. 28, 2026
Feb. 28, 2025
May 31, 2025
May 31, 2024
Cash flows from operating activities:        
Net loss $ (349,842) $ (493,710) $ (743,235) $ (614,405)
Reconciliation of net loss to net cash used in operating activities:        
Depreciation expense 14,624 15,102 20,828 20,052
Stock compensation 24,312 24,312 194,846
Deferred offering costs expensed 150,526 150,526
Noncash lease expense (15,260) 31,406 (1,830) (8,450)
Operating lease liabilities 11,831 (31,116) 1,867 7,115
Amortization of note discount 48,293 30,803 43,538 25,367
Increase (decrease) in cash resulting from changes in operating assets and liabilities        
Accounts receivable (107,400) 89,281 89,281 (89,281)
Prepaid expenses 36,136 (34,293) (77,036) (89,334)
Accounts payable and accrued expenses 467,984 49,980 83,210 108,997
Accrued interest 39,456 24,774 34,634 23,232
Deferred revenue (33,982) 43,982
Income taxes payable (176,002) 12,890 16,483 112,947
Net cash used in operating activities (64,162) (130,045) (313,440) (308,914)
Cash flows from investing activities:        
Purchases of fixed assets (6,938) (1,278)
Net cash used in investing activities (6,938) (1,278)
Cash flows from financing activities:        
Proceeds from notes payable 250,000 200,000 300,000 200,000
Net cash provided by financing activities 250,000 200,000 300,000 200,000
Net increase in cash 178,900 69,955 (13,440) (110,192)
Cash and cash equivalents at beginning of the period 56,836 70,276 70,276 180,468
Cash and cash equivalents at end of the period 235,736 140,231 56,836 70,276
Non-cash investing and financing activities:        
Discounts on note payable to founder 12,694 24,970 34,692 35,063
Supplemental disclosure of cash flow information:        
Cash paid for interest
Cash paid for taxes $ 1,456 $ 1,456